Comparison of preovulatory follicular concentrations of epidermal growth factor, insulin-like growth factor-I, and inhibins A and B in women undergoing assisted conception treatment with gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists

Uluğ, Ulun; Turan, Ersadık; Tosun, Süleyman; Erden, Halit Firat; Bahçeci, Mustafa

doi:10.1016/j.fertnstert.2006.08.102

Cited by 20 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, a recent meta analysis comparing outcomes between antagonist and agonist cycles, including 13 randomized clinical trials with a range of 2-101 pregnant cases for each study, miscarriage rates were not found to be different (11.7% vs 11.5%) [18]. However, the studies in this meta analysis in the Cochrane review did not take into account the plurality of gestations and the definitions of miscarriage were not uniform [5][6][7][8][9][10][11][12][13][14][15][16][17][18].…”

Section: Short Communicationmentioning

confidence: 83%

“…Initial randomized clinical trial (RCT) declared that neither implantation nor pregnancy rates were significantly different than agonist protocol; however, subsequent meta analysis reported inferior pregnancy rates among patients using GnRH antagonist [2][3][4][5]. Furthermore, some studies assessed ovarian compartment during stimulation with GnRH agonists and antagonists, as measured by expressions of hormones and paracrine growth factors, and none of them found significant differences in clinical outcome [6][7][8]. In order to determine whether this subtle clinical outcome difference between those GnRH analogues could be integral to endometrial microenvironment, some studies addressed endometrium as a confounding factor.…”

Section: Short Communicationmentioning

confidence: 99%

See 1 more Smart Citation

Early pregnancy loss rates were different among singleton gestations conceived by ICSI using GnRH agonist and antagonist

Bahçeci

Uluğ

Şişmanoğlu

et al. 2009

J Assist Reprod Genet

Self Cite

View full text Add to dashboard Cite

This study compared early pregnancy losses (termination of pregnancy before 12 weeks of gestation, EPL) among conceptions achieved by ICSI according to the type of GnRH analogue for ovarian stimulation. Only singleton gestations (2,184) and fresh embryo transfers were included. GnRH agonist was used in 848 gestations out of 2,184 and GnRH antagonist was used in the remaining 1,336 gestations. EPL was found to be significantly higher in GnRH antagonist gestations compared to GnRH agonist (27.2% vs 18.9%). This significant difference persisted when gestations were segregated according to maternal age, especially among women younger than 35 years old. Therefore our results suggest that gestations conceived by ovarian stimulation including GnRH antagonists may have higher propabilty of having EPL.

show abstract

Section: Short Communicationmentioning

confidence: 83%

Section: Short Communicationmentioning

confidence: 99%

Early pregnancy loss rates were different among singleton gestations conceived by ICSI using GnRH agonist and antagonist

Bahçeci

Uluğ

Şişmanoğlu

et al. 2009

J Assist Reprod Genet

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the study of Choi et al mentioned earlier, it was reported that after studying follicular IGF1, 2, IGFBP 3, 4 and PAPP-A in 2 groups of patients with different protocols, the difference in the follicular environment did not affect the IVF outcomes (pregnancy rate) [13]. Ulug et al did not see a correlation between pregnancy and follicular IGF 1 [14]. Like Cunha, Dorn, Choi and Ulug's studies we also couldn't found any correlation between follicular fluid IGF1, IGFBP 3 and pregnancy.…”

Section: Discussionmentioning

confidence: 95%

“…However, they reported that the difference of the microenvironment does not appear to result in a difference in clinical outcomes [13].Ulug et al compared the levels of follicular IGF 1, Inhibin A, Inhibin B, and epidermal growth factor in IVF patients using gonadotropin analogue and antagonists. They reported that follicular IGF 1 levels were the same in the analogue and antagonist cycles [14]. In order to homogenize our study we only included patients receiving gonadotropin analogues different from Choi and Ulug study's.…”

Section: Discussionmentioning

confidence: 99%

The effect of intrafollicular IGF 1 and IGFBP 3 on IVF outcome in patients using different gonadotropins: a prospective study

Genc

Yılmaz

Uygur

et al. 2011

J Assist Reprod Genet

View full text Add to dashboard Cite

Aim To investigate follicular fluid IGF 1, IGFBP 3 and their effects on IVF outcome in patients using different gonadotropins. Materials and methods This prospective study was performed among 92 IVF patients who were categorized according to IVF pregnancy outcome. Two groups were formed as Group1 : pregnant, Group 2: non pregnant. Results Follicular IGF 1 and IGFBP 3 levels were not different between the two groups. There were negative correlations between follicular IGF 1 and age, gonadotropin dose, embryo numbers in all patients and group 2, but there were no correlations between IGF1 and these parameters in group 1. Although IGFBP 3 levels were not different in patients using rec FSH or HMG, IGF 1 were higher in patients treated by rec FSH compared to patient using HMG. When the groups using rec FSH or HMG were analyzed according to pregnancy rate, there were no differences in IGF 1 levels. Conclusion Follicular IGF 1, IGFBP 3 do not predict clinical IVF outcome regardless of the different gonadotropin preparations.

show abstract

“…Stimulation treatment was applied for each patient as previously described (7). Briefly, to induce ovulation, human chorionic gonadotrophin (hCG) (5,000 IU; Ovidrelle; Merck Serono, UK) was injected, followed by the aspiration of follicles transvaginally after 35-36 h of the hCG injection.…”

Section: Controlled Ovarian Stimulation and Embryologymentioning

confidence: 99%

PGD management scheme for older females with balanced translocations: Do older females have less chance of balanced embryo transfer?

Tulay

Gültomruk²,

Fındıklı³

et al. 2016

J Turkish German Gynecol Assoc

Self Cite

View full text Add to dashboard Cite

Patient informationTranslocation carriers were subdivided according to maternal age (<35 years and advanced maternal age of ≥35 years) and translocation type, i.e., reciprocal and Robertsonian. A total of 20 couples with maternal ages of <35 years with 37 PGD cycles were analyzed within the reciprocal translocation carrier group. The advanced maternal age group of reciproObjective: Carriers of reciprocal and Robertsonian translocations have a higher risk of experiencing infertility and repeated miscarriages. It is well established that with advancing maternal age, the risk of aneuploidies in embryos increases. In this study, the chance of developing balanced embryos in translocation carriers with advanced maternal age was analyzed to establish a management scheme for couples seeking fertility treatment and preimplantation genetic diagnosis (PGD). Material and Methods:Biopsy was performed on cleavage-stage embryos. Multicolor fluorescence in situ hybridization was used for PGD.The translocation carriers underwent a total of 55 cycles of PGD. Genetics diagnosis and cycle outcomes of PGD cases were examined.Results: This study showed that the chance of obtaining a balanced embryo from the Robertsonian translocation carriers was significantly less when the maternal age is advanced. Similar rates for balanced embryos were obtained from the reciprocal translocation carriers. Conclusion:The results of this study show that maternal age plays an important role and that genetic counselling and planning for a PGD cycle in translocation carriers, particularly for Robertsonian carriers, must be accordingly adapted. (J Turk Ger Gynecol Assoc 2016; 17: 91-5) Keywords: PGD, maternal

show abstract

Comparison of preovulatory follicular concentrations of epidermal growth factor, insulin-like growth factor-I, and inhibins A and B in women undergoing assisted conception treatment with gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists

Cited by 20 publications

References 27 publications

Early pregnancy loss rates were different among singleton gestations conceived by ICSI using GnRH agonist and antagonist

Early pregnancy loss rates were different among singleton gestations conceived by ICSI using GnRH agonist and antagonist

The effect of intrafollicular IGF 1 and IGFBP 3 on IVF outcome in patients using different gonadotropins: a prospective study

PGD management scheme for older females with balanced translocations: Do older females have less chance of balanced embryo transfer?

Contact Info

Product

Resources

About